Carbapenem-resistant Acinetobacter baumannii Bacteremia in Liver Transplant Recipients

Acinetobacter baumannii has become an increasingly important nosocomial pathogen. Carbapenem is the preferred drug of choice for treatment of multidrug-resistant gram-negative bacilli, but carbapenem-resistant A baumannii (CRAB) has now emerged. The aim of this study was to determine the incidence, outcomes, and risk factors for CRAB bacteremia in liver transplant recipients.

Source: Transplantation Proceedings - May 1, 2018 Category: Transplant Surgery Authors: Y.J. Kim, S.I. Kim, Y.d. Lee, H.J. Choi, J.Y. Choi, S.K. Yoon, Y.-K. You, D.-G. Kim Tags: Asian Transplantation Week 2017 Source Type: research